Beilstein J. Org. Chem. 2012, 8, 1804–1813.
0.289 mmol, 1.0 equiv) in chloroform (3 mL) at 0 °C, followed 2-((3S,4R)-4-Methyl-2-oxo-1-phenylpyrrolidin-3-yl)-N-
by the appropriate chiral amine (A–I) (0.0289 mmol, 0.1 equiv) phenylacetamide (6{1,1,1}) (major syn diastereomer):
and the reaction mixture was stirred at the appropriate tempera- 1H NMR (400 MHz, CDCl3) δ 9.44 (s, 1H), 7.62–7.53 (m, 4H),
ture for the appropriate length of time listed in Table 1. Water 7.42–7.36 (m, J = 8.0 Hz, 2H), 7.32–7.24 (m, 2H), 7.22–7.16
was added upon completion of the reaction and the resulting (m, J = 9.2, 5.5 Hz, 1H), 7.10–7.03 (m, J = 7.4 Hz, 1H), 4.05
mixture was extracted with methylene chloride (3 × 5 mL). The (dd, J = 9.6, 6.0 Hz, 1H), 3.43 (dd, J = 9.7, 0.9 Hz, 1H),
methylene chloride extracts were combined, dried over sodium 3.29–3.22 (m, J = 7.8, 5.4 Hz, 1H), 3.00–2.93 (m, 1H),
sulfate and concentrated in vacuo to yield a yellow liquid. The 2.82–2.74 (m, 1H), 2.51 (dd, J = 15.3, 5.3 Hz, 1H), 1.09 (d, J =
crude liquid was purified by column chromatography (2/3 ethyl 3.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.4, 170.0,
acetate–hexane) to yield the succinimide 3{1,1} as a clear color- 139.2, 138.4, 129.0, 128.9, 125.2, 123.9, 120.3, 119.8, 54.9,
less liquid composed of a mixture of two diastereomers, which 44.7, 35.1, 30.7, 14.9; IR (neat): 3465, 3263, 2932, 2855,
were separated by further chromatographic purification.
1660 cm−1; MS (ESI+) m/e 309.2 [M + H]+; HRMS (ESI+)
calcd for C19H21N2O2 [M + H]+: 309.1603; found: 309.1606.
(R)-2-((S)-2,5-Dioxo-1-phenylpyrrolidin-3-yl)propanal
(3{1,1}) (major diastereomer):
+74.0 (c 1.10, CHCl3); 2-((3S,4S)-4-Methyl-2-oxo-1-phenylpyrrolidin-3-yl)-N-
1H NMR (400 MHz, CDCl3) δ 9.67 (s, 1H), 7.47 (m, 2H), 7.39 phenylacetamide (6{1,1,1}) (minor anti diastereomer):
(m, 1H), 7.35–7.23 (m, 2H), 3.36 (m, 1H), 3.13 (m, 1H), 2.98 1H NMR (400 MHz, CDCl3) δ 9.58 (s, 1H), 7.62–7.51 (m, 4H),
(dd, J = 18.5, 9.7 Hz, 1H), 2.51 (m, 1H), 1.30 (d, J = 7.6 Hz, 7.41–7.33 (m, 2H), 7.30–7.22 (m, J = 10.3, 5.5 Hz, 2H),
3H); 13C NMR (100 MHz, CDCl3) δ 201.4, 177.5, 175.0, 131.8, 7.22–7.12 (m, J = 7.4 Hz, 1H), 7.10–6.98 (m, J = 7.4 Hz, 1H),
129.1, 128.6, 126.4, 46.9, 39.4, 31.5, 9.7; IR (neat): 2971, 2940, 3.79 (dd, J = 9.4, 8.0 Hz, 1H), 3.42 (t, J = 9.5 Hz, 1H), 2.85 (dd,
1774, 1701 cm−1; MS (ESI+) m/e 232.1 [M + H]+; HRMS J = 14.7, 7.7 Hz, 1H), 2.72–2.61 (m, J = 12.6, 11.2, 8.8 Hz,
(ESI+) calcd for C13H14NO3 [M + H]+: 232.0974; found: 1H), 2.55 (dd, J = 14.7, 3.9 Hz, 1H), 2.33–2.14 (m, 1H), 1.22
232.0988.
(d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.7,
169.4, 138.7, 138.3, 128.8, 128.7, 125.0, 123.7, 120.1, 119.6,
(S)-2-((S)-2,5-Dioxo-1-phenylpyrrolidin-3-yl)propanal 54.1, 48.1, 37.7, 33.7, 16.6; IR (neat): 3460, 3265, 2932, 2855,
(3{1,1}) (minor diastereomer): +43.3 (c 0.80, CHCl3); 1657 cm−1; MS (ESI+) m/e 309.2 [M + H]+; HRMS (ESI+)
1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 7.47 (m, 2H), 7.39 calcd for C19H21N2O2 [M + H]+: 309.1603; found: 309.1590.
(m, 1H), 7.28 (m, 2H), 3.26–3.15 (m, J = 13.0, 6.5 Hz, 1H),
3.10–3.00 (m, 1H), 2.87 (dd, J = 18.1, 9.6 Hz, 1H), 2.54 (dd, J (S)-1-Phenyl-3-((R)-1-(phenylamino)propan-2-yl)pyrroli-
= 18.1, 5.6 Hz, 1H), 1.33 (d, J = 7.8 Hz, 3H); 13C NMR dine-2,5-dione (7{1,11}): 1H NMR (400 MHz, CDCl3) δ
(100 MHz, CDCl3) δ 201.8, 177.6, 175.1, 132.0, 129.0, 128.5, 7.50–7.33 (m, 3H), 7.24–7.08 (m, 4H), 6.79–6.67 (m, J =
126.5, 46.8, 40.6, 31.5, 11.2; IR (neat): 2973, 2941, 1773, 7.3 Hz, 1H), 6.67–6.52 (m, J = 7.5 Hz, 2H), 3.82 (s, 1H),
1701 cm−1; MS (ESI+) m/e 232.1 [M + H]+; HRMS (ESI+) 3.42–3.26 (m, 1H), 3.26–3.09 (m, 2H), 2.92 (dd, J = 18.5,
calcd for C13H14NO3 [M + H]+: 232.0974; found: 232.0985. 9.6 Hz, 1H), 2.63 (dd, J = 18.5, 5.0 Hz, 1H), 2.63–2.50 (m, J =
5.0 Hz, 1H), 1.09 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz,
General procedure for the reductive amination/
CDCl3) δ 178.5, 175.6, 147.8, 131.8, 129.3, 129.1, 128.6,
lactamization of 3{1,1} with aniline (4{1}) (Table 2)
126.6, 117.9, 112.9, 46.9, 42.4, 34.3, 31.3, 15.0; IR (neat):
Aniline (4{1}) (38.4 μL, 0.422 mmol, 1.5 equiv) and sodium 3380, 2974, 2950, 1775 cm−1; MS (ESI+) m/e 309.2 [M + H]+;
triacetoxyborohydride (119 mg, 0.562 mmol, 2.0 equiv) were HRMS (ESI+) calcd for C19H21N2O2 [M + H]+: 309.1603;
added to a solution of succinimide 3{1,1} (65.0 mg, found: 309.1595.
0.281 mmol, 1.0 equiv) in chloroform (3 mL) and the reaction
mixture was stirred at the appropriate temperature for the appro- General procedure for the combination of the
priate length of time listed in Table 2. A 1 N aqueous solution Michael addition, the reductive amination/lactamiza-
of sodium hydroxide (3 mL) was added and the reaction mix- tion, and the epimerization step in a single-pot
ture was extracted with methylene chloride (3 × 2 mL). The process to produce γ-lactam 6{1,1,1} (Scheme 4)
methylene chloride extracts were combined, dried over sodium A 0.400 M solution of propionaldehyde (2{1}) in chloroform
sulfate and concentrated in vacuo to yield a yellow liquid. The (1.50 mL, 0.600 mmol, 1.5 equiv) was added to a 0.400 M solu-
crude liquid was purified by column chromatography (1/1 ethyl tion of N-phenylmaleimide (1{1}) in chloroform (1.00 mL,
acetate-hexane) to yield 6{1,1,1} as a clear colorless liquid 0.400 mmol, 1.0 equiv) at 0 °C, followed by a 0.100 M
composed of a mixture of two diastereomers and 7{1,1,1} as a solution of (S)-(−)-α,α-diphenyl-2-pyrrolidinemethanol
clear colorless liquid.
trimethylsilyl ether (0.40 mL, 0.040 mmol, 0.10 equiv), and the
1811